Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT01869881

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01869881
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01869881. Randomized; double masking; primary purpose treatment. Start 2013-02-01 (actual); primary completion 2014-11-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
Condition
Diabetic Nephropathy
Intervention (Drug)
Anplag(Sarpogrelate)
Intervention (Drug)
Placebo
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct01869881
Content hash
f5d84f00c9e72dbbb9213000c033cb3f12441629c369991f0db5e342a378dd71